Analysis of hMLH1 and hMSH2 expression in cisplatin-treated ovarian cancer patients

Ginekologia Polska

Volumn 79, Issue 12, 2008, Pages 826-834

  Magnowska, Magdalena ^a   Surowiak, Pawel ^b,c   Nowak Markwitz, Ewa ^a   Michalak, Marcin ^a   Magnowski, Piotr ^a   Wojeiech, Rokita ^d   Kedzia, Helena ^e   Zabel, Maciej ^a,b   Spaczyński, Marek ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c Dolnoslaskie Centrum Onkologii Wroclaw   (Poland)

^d City Hospital   (Poland)

^e GPSK UM ^*  (Poland)

Author keywords

Cisplatin; DNA mismatch repair; Drug resistance; hHSH2; hMLH1; Immunohistochemistry; Ovarian cancer

Indexed keywords

EID: 59349087305     PISSN: 00170011     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Williams C, Mead G, Macbeth F, [et al.]. Cisplatin combination chemotherapy versus chlorambucil in advanced ovarian carcinoma: mature results of a randomised trial. J Clin Oncol. 1985, 3, 1455-1462.
2. Markman M, Rothman R, Hakes T, [et al.]. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 1991, 9, 389-393.
3. Acharya S, Wilson T, Gradia S, [et al.]. hMSH2 forms specific mispair-binding complexes with hMSH3 and hMSH6. Proc Natl Acad Sci USA. 1996, 93, 13629-13634.
4. Mello J, Acharya S, Fishel R, [et al.]. The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin. Chem Biol. 1996, 3, 579-589.
5. Peltomaki P. Role of DNA mismatch repair defects in the pathogenesis of human cancer. J Clin Oncol. 2003, 21, 1174-1179.
6. Marcus V, Madlensky L, Gryfe R, [et al.]. Immunohistochemistry for hMLH1 and hMSH2: A practical test for DNA mismatch repair-deficient tumors. Am J Surg Pathol. 1999, 23, 1248-1255.
7. Fink D, Nebel S, Aebi S, [et al.]. The role of DNA mismatch repair in platinum drug resistance. Cancer Res. 1996, 56, 4881-4886.
8. Sobin L, Wittekind C. (eds): TNM Classification of Malignant Tumors. New York: UICC Wiley-Liss, 2002.
9. Shimizu T, Kamoi S, Amada S, [et al.]. Toward the development of a universal grading system for ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up. Cancer. 1998, 82, 893-901.
10. Remmele W, Stegner H: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 1987, 8, 138-140.
11. Strathdee G, MacKean M, Illand M, [et al.]. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene. 1999, 18, 2335-2341.
12. Aebi S, Kurdi-Haidar B, Gordon R, [et al.]. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res. 1996, 56, 3087-3090.
13. Kupyjańczyk J. Clinical value of molecular changes in ovarian carcinoma. Rep Prac Oncol Radiother. 2004, 9, 149-155.
14. Howell S, Kurdi-Haidar B, Christen R, [et al.]. Molecular mechanisms of platinum drug resistance. In: Ovarian Cancer 4. Ed. Sharp F, Blackett T, Leake R, [et al.]. Chapmann&Hall Medical, 1996.
15. Brown R, Hirst G, Gallagher W, [et al.]. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene. 1997, 15, 45-52.
16. Samimi G, Fink D, Varki N, [et al.]. Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy. Clin Cancer Res. 2000, 6, 1415-1421.
17. Materna V, Surowiak P, Markwitz E, [et al.]. Expression of factors involved in regulation of DNA mismatch repair- and apoptosis pathways in ovarian cancer patients. Oncol Rep. 2007, 17, 505-516.